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Background: Purine receptors participate in peripheral and central sensitization and are associated with migraine
headache. We investigated the role of P2X7 receptor (P2X7) in a nitroglycerin (NTG)-induced mouse model of
migraine.
Methods: Intraperitoneal NTG injection (15 mg/kg) triggered thermal hyperalgesia in the hindpaws of wild-type
C57BL/6J mice, followed by the induction of c-fos in upper cervical spinal cord and trigeminal nucleus caudalis. The
effect of genetic deletion of P2X7 and the selective P2X7 antagonist Brilliant Blue G (BBG) were examined on hyperalgesia
and c-fos induction.
Results: NTG decreased the paw withdrawal threshold in both wild-type and P2X7 knockout mice. Nevertheless, subacute
BBG treatment (50 mg/kg/day i.p.) completely prevented the effect of NTG in wild-type, but not in knockout
mice. Whereas P2X7 deficiency differentially affected the expression of c-fos, the average number of fos-immuno-reactive
neurons in trigeminal nucleus caudalis, but not in upper cervical spinal cord was lower in BBG-treated wild-type mice after
NTG treatment.
Conclusions: Our results show that P2X7 receptors might participate in the pathogenesis of migraine, although
upregulation of other P2X receptors probably compensate for the loss of its action in knockout mice. The data also
suggest the therapeutic potential of P2X7 antagonists for the treatment of migraine.
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Headache is a common pain disorder affecting an esti-
mated 11% of the general population [1] and the global
prevalence of chronic migraine is 0.5-1% [2]. Despite in-
creasing knowledge regarding migraine pathophysiology,
drug therapies used for prevention and treatment of
symptoms remain unsatisfactory for many patients.
Therefore, it is necessary to continue development of
new drugs and to identify promising new cellular or
molecular targets [3].
Migraine is a complex brain disorder, characterized by
predominantly unilateral pulsating head pain, which can be
aggravated by routine physical activity and accompanied by* Correspondence: sperlagh@koki.hu
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reproduction in any medium, provided the origneurological symptoms including nausea, vomiting, hyper-
sensitivity to light, sound and smell and visual disturbances
as well as cognitive, emotional and motor disturbances. Be-
fore and during migraine attacks, headache is accompanied
by increased skin sensitivity to touch, heat and cold (cuta-
neous allodynia) [4,5] and normally innocuous stimuli can
be unpleasant and painful.
Among the variety of experimental models of migraine
attacks, nitroglycerin (NTG) is amongst the most widely
used and accepted approaches, in both animals and hu-
man [6]. Several reports show that the clinical use of
NTG induces delayed spontaneous headache in migraine
patients [7-9] coupled with accompanying symptoms.
NTG-derived nitric oxide (NO) activates brainstem re-
gions and neuronal populations which are involved in
environmentally triggered migraine attacks [10] and
prophylactic agents can block NTG-induced headachesger. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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neous allodynia in migraine sufferers [13] including in
non-cranial regions [4,5]. Previous studies showed that
systemic administration of NTG induces hyperalgesia of
the hindpaws, which is inhibited by the antimigraine
drug sumatriptan in mice [14]. These observations valid-
ate extrafacial thermal and mechanical hyperalgesia as a
potential behavioural correlate of migraine in mice sub-
jected to NTG. NTG administration also activates neur-
onal populations in selected areas of the brain that are
primarily involved in the transmission of cephalic pain,
including the trigeminal nucleus caudalis (TNC) in ro-
dents [14-16]. Chemical activation of the C-fibers of the
trigeminal nerve - leading to transmission of nociceptive
information into the brainstem - induces c-fos expres-
sion within specific areas of the TNC. This is inhibited
by anti-migraine therapeutics, such as olcegepant [17].
These findings indicate that those drugs, which influence
c-fos expression in the TNC might have relevance in the
mediation of potential anti-migraine effects.
The purinergic signalling system consists of enzymes,
transporters and receptors responsible for the action of
extracellular nucleotides, particularly ATP and adeno-
sine. The actions of extracellular nucleotides are medi-
ated by various subtypes of ionotropic P2X (P2X1-7)
and metabotropic P2Y (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11,
P2Y12, P2Y13, P2Y14) receptors. The potential involve-
ment of the purinergic signalling system in the patho-
physiology of migraine was recognized more than thirty
years ago [18]. Since then, the role of different subtypes
of P2 receptors has been elucidated in different pain mo-
dalities, amongst which, the role of P2X3, and various
P2Y receptor subtypes have already been proposed and
examined in cellular and animal models of migraine
[19-24]. ATP is released during spreading depression
(SD), a phenomenon thought to underlie aura both
in vitro [25] and in vivo [26], which raises the possibility
that endogenous purines could act as potential triggers
or mediators of migraine.
P2X7 receptors (P2X7) belong to the P2X family of re-
ceptors, which are ligand-gated, non-selective cation
channels. P2X7 is widely expressed in various cell types
involved in pain transmission, including neurons, micro-
glia, satellite glial cells, astrocytes in dorsal root ganglia,
trigeminal ganglia and the dorsal horn of the spinal cord
e.g. [27-29]. Several studies have demonstrated that
P2X7 is involved in the modulation of pathological noci-
ception. P2X7 knockout mice showed a lack of hyper-
sensitivity to mechanical and thermal stimuli [30,31] and
P2X7-specific antagonists have consistently been shown
to be protective in animal models of inflammatory
[32-34] and neuropathic pain [33,35]. Moreover, recent
studies have highlighted that variation within the gene
encoding P2X7 can affect chronic pain sensitivity in bothmouse and human [36]. The role of P2X7, however, has
not examined in any whole animal model of migraine.
The objective of this study, therefore, was to examine
how genetic deletion and pharmacological blockade of
P2X7 affects NTG-induced thermal hypersensitivity and
c-fos induction in migraine related CNS areas in mice.
We report here that although genetic deletion of P2X7
(P2X7−/−) results in non-significant changes in the noci-
ceptive threshold after NTG treatment, the selective
P2X7 antagonist, BBG completely prevents the effect of
NTG in wild-type, but not in P2X7−/− mice and also al-
leviates NTG-induced c-fos expression.
Methods
Animals
All experiments were conducted in accordance with the
principles and procedures outlined in Guide for the Care
and Use of Laboratory Animals of the National Institute
of Health. The local Animal Care Committee of the
Board of the Institute of Experimental Medicine, Hungarian
Academy of Sciences approved all experimental procedures
(Permission No: 22.1/3671/003/2008). This study used drug
and test naïve, 3-month old (approx. 30 g), male wild-type
(P2X7+/+), and P2X7 knockout mice (P2X7−/−). Breeding
pairs of P2X7−/− homozygote knockout mice (C57BL/6J
based) were originally supplied by Christopher Gabel (Pfi-
zer Inc., Groton, CT, USA). The animals contained the
DNA constructs P2X7-F1 (5_-CGGCGTGCGTTTTGA
CATCCT-3_) and P2X7-R2 (5_-AGGGCCCTGCGGTT
CTC-3_), which have previously been shown to produce
genetic deletion of P2X7 [37]. Homozygous knockout mice
(P2X7−/−) and P2X7+/+ (C57BL/6) littermates were bred
in the local animal house (IEM HAS, SPF Unit). The geno-
type of the mice was tested by PCR analysis as previously
described [37]. Mice were housed under standard labora-
tory conditions with food and water available ad libitum, in
a 12-h light–dark cycle at a temperature of 21–23°C. All
efforts were made to minimize animal suffering and reduce
the number of animals used. Experiments were carried out
between 9:00 and 14:00 in the same room in which the ani-
mals were housed, whilst perfusion took place in a different
room.
Drugs and treatments
A modified version of NTG model described by Bates
et al. [14] was used. Animals received intraperitoneal
(i.p.) injections of 15 mg/kg NTG (Nitro POHL®, G.
Pohl-Boskamp GmbH & Co. KG, Hohenlockstedt,
Germany) or vehicle (49 mg glucose monohydrate/ml)
after the measurement of the baseline thermal noci-
ceptive threshold. The dose of NTG was chosen based
on literature data [14] and preliminary tests. Sumatriptan
succinate (Sigma-Aldrich, Hungary), dissolved in saline was
used to validate our experiments: each animal was given i.p.
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minutes after NTG administration. The P2X7 antagonist,
Brilliant Blue G (BBG, Sigma-Aldrich, Hungary) or its
vehicle (0.9% saline), were applied in an identical way, or
using two different prophylactic application protocols:
acutely (50 mg/kg), it was applied i.p. 30 minutes prior to
NTG treatment and after the measurement of the baseline
thermal nociceptive threshold on the day of testing. In sub-
acute treatment, mice were treated for 5 consecutive days
with the daily doses of BBG (50 mg/kg i.p.) or saline and
30 min after the last injection were subjected to NTG.
Selection of dose was based on previous studies [38,39]. All
drug solutions were freshly prepared on the day of use.
Increased temperature hot plate test (ITHT)
Mice were randomly assigned to experimental groups of
10–13 and housed 5 per cage for 1 week prior to experi-
mentation. An Excel protocol was used to randomize
the animals, and codes unblinded only after the experi-
ment. Responsiveness of mice to nociceptive stimulation
was measured by an increasing-temperature hot plate
system (IITC Life Science, Woodland Hills, CA, USA).
On the day of testing, animals were habituated to the
testing apparatus for 10 min prior to determination of
baseline nociceptive threshold. The animals were placed
on an electrically heated metal plate that was kept at a
constant temperature of 30°C (starting temperature).
After the habituation period the plate was heated from
the starting temperature with a constant rate of 6°C/
min, until the animals showed nocifensive behaviour
(frequent pawlifting and/or pawlicking in both front and
back paws, jumping).
Heating was then instantly stopped, the animal re-
moved from the apparatus and the plate rapidly cooled.
The temperature at which the animal showed the first
sign of nocifensive behaviour was taken as the paw with-
drawal threshold (PWT), expressed in °C. Approximately
1 hour later, the measurement was repeated and the
average of two values was taken as the baseline thermal
nociceptive threshold. After the second measurement,
the animals received treatment with drugs as described
above and one and two hours after nitroglycerin admin-
istration, post-drug nociceptive threshold was measured.
Immunohistochemistry (IHC)
Among animals undergoing behavioural testing, 5–8 mice/
experimental group were selected by randomization prior
to experimentation and were assigned to be the subject of
subsequent perfusion and immunohistochemistry. Two
hours following i.p. injection of NTG (15 mg/kg) or vehicle,
mice were anaesthetized with ketamine and xylazine (i.p.)
and perfused with fixative solution (containing 0.5% borax
(Na2B4O7 10 H2O) and 5% paraformaldehyde). Whole
brain and spinal cord were removed and fixed for 3 h in 5%paraformaldehyde, and transferred to 30% sucrose in fixa-
tive solution for 20–24 h. Samples were then frozen and
transverse sections cut at 30 μm. Every fourth section was
collected for free-floating IHC. After blocking the endogen-
ous peroxidase activity with 0.3% hydrogen-peroxide, sec-
tions were incubated in 0.3% Triton X-100 and 2% normal
goat serum for 1 h, followed by incubation with anti-fos
(raised in rabbit, 1:10000, 72 h at 4°C, sc-52, Santa Cruz
Biotechnology). Sections were then washed in PBS before
incubation for 1 h in biotinylated goat anti-rabbit secondary
antibody, and incubated with avidin-biotin-complex (Vec-
tastain – ABC kit PK-6100 Elite, 1 h). Peroxidase activity
was detected with 3,3′-diaminobenzidine (Sigma-Aldrich,
Hungary). Mounted and coverslipped sections were
microphotographed and fos-immuno-reactive nuclei
were counted within both sides of the cervical spinal
cord and the TNC using ImageJ software. We counted
30 hemi-sections from each hemisphere per animal
(TNC) and 10 hemi-sections from each hemisphere
per animal (cervical spinal cord) and calculated the
average number of c-fos positive nuclei in each section.
Statistics
All data were expressed as means ± SEM of n observa-
tions. For statistical comparison of thermal sensitivity
after treatments in P2X7+/+ and P2X7−/− mice, a re-
peated measures analysis of variance ANOVA was used
to identify genotype, treatment and time effects. The
number of c-fos positive nuclei in spinal cord and TNC
was compared by two-way ANOVA. Where the variance
was not homogeneous based on a significant Levene’s
test, we used the Kruskal-Wallis nonparametric test. The
Fischer LSD test was used for post hoc comparison. For
pairwise comparisons, the Student t test was used. All
tests were performed by the STATISTICA software
package (StatSoft, Tulsa, OK, USA).
Results
Effect of genetic deletion of P2X7 on NTG-induced ther-
mal hypersensitivity
The baseline nociceptive threshold in wild-type (P2X7+/+)
mice was 45.95 ± 0.14°C (n = 68). NTG significantly
and time-dependently reduced PWT, when compared
with vehicle treatment (at 1 h: 100.70 ± 1.25%, n = 12;
and 93.56 ± 0.95%, n = 13; 2 h: 100.92 ± 1.13%, n = 12;
and 95.06 ± 1.13%, n = 13, in vehicle and NTG-treated
mice, respectively, ***P < 0.0001; Figure 1).
For the validation of the model, the antimigraine drug
sumatriptan (600 μg/kg i.p.) was chosen as it is known
to reverse NTG-induced thermal hypersensitivity in
mice [14]. In P2X7+/+ mice, treated with sumatriptan
5 min after NTG, PWT was higher than in mice treated
with an identical volume of saline (at 1 h: 98.74 ± 1.66%,
n = 10; 93.43 ± 1.80%, n = 10, p = 0.0375 in NTG +
Figure 1 NTG induces thermal hypersensitivity in wild-type and
P2X7 knockout mice. The changes in nociceptive threshold after
i.p. NTG treatment are presented on the graph, as PWT, expressed in
% of baseline. PWT was decreased in animals that received 15 mg/
kg NTG compared with animals that received vehicle (ANOVA, effect
of treatment, F1,41 = 37.34, p < 0.0001). NTG-induced decrease in PWT
was not significantly different in wild-type and knockout mice. Asterisks
denote significant changes between respective PWT values of
vehicle- and NTG-treated mice (n = 10-13 animals/group; ANOVA
+ Fischer LSD post hoc test, *P < 0.05, **P < 0.01, ***P < 0.001).
Figure 2 The effect of symptomatic treatment with sumatriptan
and P2X7-selective antagonist BBG. Wild-type mice were treated
with 600 μg/kg sumatriptan/50 mg/kg BBG i.p. or an identical volume
of saline 5 min after NTG treatment. PWT is expressed in % of baseline.
Asterisk indicate significant changes between respective PWT values
of saline- and sumatriptan-treated mice (n = 10 animals/group;
ANOVA + Fischer LSD post hoc test, *P < 0.05).
Gölöncsér and Sperlágh The Journal of Headache and Pain 2014, 15:24 Page 4 of 8
http://www.thejournalofheadacheandpain.com/content/15/1/24sumatriptan and NTG+ saline treated mice, respectively,
Figure 2).
In P2X7−/− mice, the baseline PWT values were not sig-
nificantly different from P2X7+/+ mice (45.47 ± 0.23°C, n =
20; p = 0.1015; Student’s t-test). Likewise, the NTG-induced
decrease in PWT was not significantly different in wild-
type and knockout mice (ANOVA genotype × treatment ef-
fect F1,41 = 1.00, p = 0.3243; Figure 1).
P2X7R antagonist prevents NTG-induced thermal
hypersensitivity
Next, we asked whether systemic administration of a spe-
cific P2X7 antagonist, BBG, can alleviate NTG-induced
thermal allodynia in mice. When administered 5 min after
the NTG injection, BBG had no effect on thermal hyper-
sensitivity in wild-type mice (Figure 2). However, when
BBG was given as a prophylactic agent, 30 min before ad-
ministration of NTG, it was already effective upon single
application (Figure 3), and it completely prevented the ef-
fect of NTG after 5-days treatment in wild-type mice. In
contrast, an identical BBG administration was ineffective in
NTG-treated P2X7 knockout mice (ANOVA genotype ×
treatment effect F1,45 = 6.36, p = 0.0153; Figure 4). The 5-
day treatment with BBG did not change the baseline ther-
mal sensitivity of either genotype (P2X7+/+: 44.38 ± 0.27°C,n = 16; p = 0.9929, P2X7−/−: 44.86 ± 0.39°C, n = 17; p =
0.167 vs. baseline PWT, Student’s t-test).NTG induced c-fos expression in trigeminal nucleus and
spinal cord
As an index of activation of the nociceptive fibres impli-
cated in migraine, changes in the average number of c-
fos-immuno-reactive nuclei in the upper cervical dorsal
horn and TNC 2 h after 15 mg/kg NTG injection were
quantified. In line with previous findings [14,15], NTG
profoundly increased c-fos expression in both areas,
when compared to vehicle-treated animals (Figure 5). In
knockout mice, NTG caused the same elevation in c-fos
expression in TNC, compared with vehicle, whereas
the c-fos level was slightly lower in the spinal cord
(Figure 5A). Two-way ANOVA of the c-fos data in the
C1-2 and TNC indicated a significant effect of NTG
treatment, without an interaction effect of genotype with
NTG (C1-2: F1,19 = 13.92, p = 0.0014; TNC: F1,19 = 48.14,
p < 0.0001). Due to unequal variance, a Kruskal-Wallis
nonparametric test was used for comparison of groups.
It indicated that NTG significantly increased c-fos levels
in the C1-2 of wild-type (WT: p = 0.0374; KO: p =
0.0679) and TNC of wild-type and knockout mice, re-
spectively (WT: p = 0.0039; KO: p = 0.0062). Further,
post hoc testing by Fischer LSD test revealed that NTG
significantly increased fos level in the C1-2 and TNC of
wild-type and knockout mice (Figure 5A).
Figure 4 Subacute treatment with BBG reverses NTG-induced
thermal hypersensitivity in wild-type mice, but not in P2X7
knockout mice. Mice were treated for 5 consecutive days with
daily doses BBG (50 mg/kg i.p.) or saline and on the fifth day NTG
was given 30 min after BBG or saline and then submitted to the
ITHT. PWT is expressed in % of baseline. Asterisks indicate significant
changes between respective PWT values of saline- and BBG-treated
mice (n = 9-16 animals/group; ANOVA + Fischer LSD post hoc test,
**P < 0.01).
Figure 3 Acute prophylactic BBG treatment alleviates NTG-
induced thermal hypersensitivity in wild-type mice. Mice were
treated with 50 mg/kg BBG i.p. or an identical volume of saline
30 min before NTG treatment. PWT is expressed in % of baseline.
Asterisks indicate statistical significant difference in respective
PWT values from the saline-treated animals (n = 11-12 mice/
group; Student’s t-test, **P < 0.01).
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kg i.p.) elicited a reduction in the level of c-fos after NTG
treatment in TNC in wild-type mice, which was significant,
when compared to an identical saline treatment (Figure 5F,
G and H, 106.63 ± 3.99, n = 8; 132.68, n = 6; p = 0.0022, in
BBG+NTG and saline +NTG treated mice, Student t test,
respectively).
Discussion
The principal new finding of the present study is that
antagonism of P2X7 by treatment with the specific P2X7
antagonist BBG leads to the alleviation of NTG-induced
thermal hypersensitivity in mice. Moreover, as BBG
treatment was ineffective in mice lacking P2X7, it is rea-
sonable to assume that its effect is mediated by P2X7.
The NTG-evoked c-fos expression in the TNC was also
attenuated after subacute BBG treatment, which implicates
a role for the TNC in mediating the effect of BBG on
NTG-induced thermal hypersensitivity. All these findings
implicate the therapeutic potential of P2X7 blockade in
migraine.
We have used the NTG-induced migraine model de-
scribed recently by Bates et al. [14] and reproduced find-
ings showing that i.p. injection of NTG elicits thermal
hypersensitivity in a time-dependent manner. We have
also replicated the finding that NTG-induced thermal
hypersensitivity is attenuated by the antimigraine drug,
sumatriptan, and is followed by the expression of c-fos
in the trigeminal nucleus of the brainstem and upper
spinal cord [14]. Although the dose of NTG necessary toinduce a significant drop in PWT (15 mg/kg), was some-
what higher than used by Bates et al. [14], this may be
explained by differences in the source of NTG, or by the
variation in the tests used to evaluate thermal nociception
(Hargreaves test vs. ITHT). The interspecies variations in
NTG sensitivity are well known and may be due to differ-
ences in the efficiency of hepatic bioactivation of NTG into
the pharmacologically active NO [40]. This might also ac-
count for slight differences between NTG responsiveness
observed in different rodent species [14-16].
Following the study of Almási et al. [41], we have used
the ITHT to measure thermal nociceptive threshold, in our
experiments instead of the widely used latency measure-
ments. As reported in this study, ITHT is a more accurate
assay of thermal hyperalgesia although the changes in re-
sponse to traditional analgesic drugs, such as diclofenac
and paracetamol, are not more than 2.0-2.5°C in this test.
Accordingly, similar changes were measured, in re-
sponse to the antimigraine drug sumatriptan, indicat-
ing that the assay system reflects changes specific to
antimigraine therapy.
Interestingly, no differences in NTG-induced thermal
hypersensitivity in P2X7−/− mice were detected, when
compared to their wild-type counterparts. The most
likely explanation for this negative finding is the
Figure 5 NTG-induced fos expression in wild-type and P2X7 knockout mice. A. Quantification of fos-immuno-reactive nuclei in upper cer-
vical spinal cord (C1-2) and TNC 2 h after 15 mg/kg NTG or vehicle. We counted 10 hemi-sections from each hemisphere for upper cervical spinal
cord, and 30 hemi-sections from each hemisphere that included TNC from both sides (n = 5-6 animal/group; Kruskal-Wallis nonparametric ANOVA
followed by Fischer LSD post hoc test, *P < 0.05, **P < 0.01, ***P < 0.001). F. The subacute BBG treatment (50 mg/kg i.p.) decreased the number of
c-fos immuno-reactive cells in TNC, but not in C1-2 in wild-type mice (n = 6-8 animal/group; Student t test **P < 0.01). B,C,D,E,G,H Representative
examples of c-fos immuno-reactivity in the TNC 2 h after i.p. administration of vehicle or 15 mg/kg NTG in P2X7+/+ (B,C) and P2X7−/− mice (D,
E), and after subacute BBG (50 mg/kg i.p.) or saline + 15 mg/kg NTG treatment in P2X7 +/+ mice (G,H), shown here with a 10× objective.
Gölöncsér and Sperlágh The Journal of Headache and Pain 2014, 15:24 Page 6 of 8
http://www.thejournalofheadacheandpain.com/content/15/1/24potential developmental upregulation of non-P2X7
P2X receptors in P2X7−/− mice, such as P2X3 or
P2X4. In fact we have previously shown the upregula-
tion of P2X4 mRNA in mice deficient of P2X7 [42].
When applied prophylactically, however, both acute
and subacute BBG treatment was effective in the allevi-
ation of NTG-induced thermal hypersensitivity in the
P2X7+/+mice. BBG is known to permeate the blood
brain barrier, and is thought to be specific to P2X7 in
the applied dose. Although in vitro experiments revealed
that BBG can inhibit Na+ channels in micromolar con-
centrations [43], in in vivo studies using a similar dose
(45.5 mg/kg), BBG has not reached higher concentra-
tions in the brain than 200 nM [44], which is selective
for P2X7 [45]. The finding that its effect was completely
lost in P2X7−/− mice also refutes the possibility of other
target for BBG than P2X7 in these experiments.
Although further experiments are necessary to clarify this
issue, there are several potential mechanisms, wherebyendogenous P2X7 could participate in the sensitization of
the trigeminovascular system. ATP is a well-known danger-
signal, which is released in response to cell injury, inflam-
mation, mechanical and metabolic distress, and is per se an
algogenic substance [46,47]. P2X7 is a ligand-gated cation
channel with high Ca2+ permeability, which participates in
pain transmission in various ways. In the dorsal root gan-
glia P2X7 is expressed on satellite glia and potentiate
P2X3 receptor mediated signalling by the release of
pro-inflammatory cytokine TNF-α [48]. An analogous
mechanism might also play a part in migraine, as satel-
lite glia of the trigeminal ganglion express P2X7 [49]
and P2X3 receptors participate in craniofacial pain by
interacting with NGF, substance P and CGRP [20,22].
P2X3 receptors also display an enhanced activity in a
genetic animal model of migraine [50]. Alternatively,
P2X7 antagonists may act more centrally, at the level
of the upper cervical spinal cord or trigeminal nucleus.
P2X7 modulates the afferent nociceptive information
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[35] and its activation participates in the central
sensitization underlying hindpaw hyperalgesia [34]. Be-
cause moderate-high density of P2X7 receptor binding
sites were found in the grey matter of the trigeminal
nucleus [28] the detected alleviation of NTG induced
c-fos expression in response to BBG indicates that the
TNC is a potential target area for the action of P2X7
receptor antagonists. The activation of P2X7 releases
excitatory amino acids in this area [27], the blockade of
which might underlie the action of BBG.
Furthermore, P2X7 is also expressed in other areas of
the brain [28]; therefore, a supraspinal action through
diencephalic, brainstem or cortical regions cannot be ex-
cluded [51]. Finally, P2X7 is expressed on circulating
and locally recruited immune cells and the best charac-
terized action of P2X7 activation is its role in the post-
translational processing of pro-inflammatory cytokines,
IL-1β and TNF−α [30,37,52], which are also known algo-
genic substances.
Conclusion
The data present here indicates that inhibition of P2X7
might be a potential target for the prophylaxis of migraine.
Moreover, because BBG is a closed structural analogue of a
US Food and Drug Administration (FDA)–approved non-
toxic food dye [53,54], our data argues for its evaluation in
a human NTG-induced migraine model.
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